New and emerging therapies for Clostridium difficile infection

Current Opinion in Infectious Diseases

Volumn 29, Issue 6, 2016, Pages 546-554

  Martin, Jessica ^a   Wilcox, Mark ^a,b,c,d  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d LEEDS GENERAL INFIRMARY   (United Kingdom)

Author keywords

Antibiotics; Antibodies; Live biotherapeutics; Vaccines

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BACTERIAL VACCINE; BEZLOTOXUMAB; CADAZOLID; CLOSTRIDIUM VACCINE; MONOCLONAL ANTIBODY; RBX 2660; RIDINILAZOLE; SER 109; SUROTOMYCIN; UNCLASSIFIED DRUG; BENZIMIDAZOLE DERIVATIVE; CB-183,315; CYCLOPEPTIDE; LIPOPEPTIDE; NEUTRALIZING ANTIBODY; OXAZOLIDINONE DERIVATIVE; PYRIDINE DERIVATIVE;

ACTIVE IMMUNIZATION; ANTIMICROBIAL THERAPY; BACTERIAL MICROBIOME; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE INFECTION; DRUG SAFETY; FECAL MICROBIOTA TRANSPLANTATION; FREEZE THAWING; HEALTH CARE QUALITY; HOST; HUMAN; IMMUNITY; INFECTION PREVENTION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; CLOSTRIDIUM INFECTION; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; RECURRENT DISEASE; SECONDARY PREVENTION;

ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; BENZIMIDAZOLES; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECAL MICROBIOTA TRANSPLANTATION; HUMANS; LIPOPEPTIDES; OXAZOLIDINONES; PEPTIDES, CYCLIC; PYRIDINES; RECURRENCE; SECONDARY PREVENTION;

EID: 84991447029     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0000000000000320     Document Type: Review

References (63)

1. CDC. 2013 Annual Report for the Emerging Infections Program for Clostridium difficile Infection. https://www.cdc.gov/hai/eip/pdf/2013-Annual- Report-12-8-2015.pdf. [Accessed 19 September 2016].
2. Public Health England. Annual Epidemiological Commentary. Mandatory MRSA, MSSA and E. coli bacteraemia and C. difficile infection data 2015/16. https://www.gov.uk/government/statistics/mrsa-mssa-ande- coli-bacteraemia-and-c-difficile-infection-annual-epidemiological-comme ntary. [Accessed 19 September 2016].
3. Knetsch CW, Connor TR, Mutreja A, et al. Whole genome sequencing reveals potential spread of Clostridium difficile between humans and farm animals in the Netherlands 2002 to 2011. Euro Surveill 2014; 19: 20954.
4. Thitaram SN, Frank JF, Siragusa GR, et al. Antimicrobial susceptibility of Clostridium difficile isolated from food animals on farms. Intl J Food Microbiol 2016; 227: 1-5.
5. Knight DR, Squire MM, Riley TV. Nationwide surveillance study of Clostridium difficile in Australian neonatal pigs shows high prevalence and heterogeneity of PCR ribotypes. Appl Environ Microbiol 2015; 81: 119-123.
6. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Contr Hospital Epidemiol 2010; 31: 431-455.
7. Surawicz CM, Brandt LJ, Binion DG, et al.Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 2013; 108: 478-498.
8. Van Nood E, Dijkgraaf MG, Keller JJ. Duodenal infusion of feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 2145.
9. Cammarota G, Masucci L, Ianiro G, et al. Randomised clinical trial: Faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection. Aliment Pharmacol Ther 2015; 41: 835-843.
10. Chang JY, Antonopoulos DA, Kalra A, et al. Decreased diversity of the fecal microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 2008; 197: 435-438.
11. Solomon K, Martin AJ, O'Donoghue C, et al. Mortality in patients with Clostridium difficile infection correlates with host pro-inflammatory and humoral immune responses. J Med Microbiol 2013; 62: 1453-1460.
12. Soriano MM, Johnson S. Treatment of Clostridium difficile infections. Infect Dis Clin North Am 2015; 29: 93-108.
13. Johnson S, Louie TJ, Gerding DN, et al., Polymer Alternative for CDI Treatment (PACT) investigators. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: Results from two multinational, randomized, controlled trials. Clin Infect Dis 2014; 59: 345-354.
14. Venugopal AA, Johnson S. Fidaxomicin: A novel macrocyclic antibiotic approved for treatment of Clostridium difficile infection. Clin Infect Dis 2012; 54: 568-574.
15. Tannock GW, Munro K, Taylor C, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology 2010; 156: 3354-3359.
16. Shue YK, Sears PS, Shangle S, et al. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses. Antimicrob Agents Chemother 2008; 52: 1391-1395.
17. Chilton CH, CrowtherGS, Freeman J, et al. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure. J Antimicrob Chemother 2014; 69: 451-462.
18. Cornely OA, Crook DW, Esposito R, et al., OPT-80-004 Clinical Study Group. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, noninferiority, randomised controlled trial. Lancet Infect Dis 2012; 12: 281-289.
19. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-431.
20. Nathwani D, Cornely OA, Van Engen AK, et al. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother 2014; 69: 2901-2912.
21. Goldenberg SD, Brown S, Edwards L, et al. The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: A series of local service evaluations. Eur J Clin Microbiol Infect Dis 2016; 35: 251-259.
22. Mascio CT, Mortin LI, Howland KT, et al. In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile. Antimicrob Agents Chemother 2012; 56: 5023-5030.
23. Alam MZ, Wu X, Mascio C, et al. Mode of action and bactericidal properties of surotomycin against growing and nongrowing Clostridium difficile. Antimicrob Agents Chemother 2015; 59: 5165-5170.
24. Bouillaut L, McBride S, Sorg JA, et al. Effects of surotomycin on Clostridium difficile viability and toxin production in vitro. Antimicrob Agents Chemother 2015; 59: 4199-4205.
25. Reigadas E, Alcalá L, Marín M, et al. In vitro activity of surotomycin against contemporary clinical isolates of toxigenic Clostridium difficile strains obtained in Spain. J Antimicrob Chemother 2015; 70: 2311-2315.
26. Cannon K, Byrne B, Happe J, et al. Enteric microbiome profiles during a phase 2 clinical trial of CB-183,315 or vancomycin for treatment of Clostridium difficile infection. European Congress of Clinical Microbiology and Infectious Disease, London, UK; 2012. Abstract P2250.
27. Chesnel L, Sambol S, Gerding D, et al. Treatment of CDAD with oral CB-183 315: Time to recurrence, relapse and re-infection rates compared with vancomycin. Clin Microbiol Infect 2012; 18 (Suppl 3): 380.
28. Boix V, Pesant Y, Fedorak RN, et al. Primary clinical outcomes from a phase 3, randomized, double-blind, active-controlled study of surotomycin in patients with Clostridium difficile-associated diarrhea. European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam; 2016. Abstract P0612.
29. Gehin M, Desnica B, Dingemanse J. Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection. Intl J Antimicrob Agents 2015; 46: 576-581.
30. Chilton CH, Crowther GS, Baines SD, et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother 2014; 69: 697-705.
31. Baldoni D, Gutierrez M, Timmer W, Dingemanse J. Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: Safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses. J Antimicrob Chemother 2014; 69: 706-714.
32. Louie T, Nord CE, Talbot GH,et al.Multicenter,double-blind, randomized, phase 2 study evaluating the novel antibiotic cadazolid in patients with Clostridium difficile infection. Antimicrob Agents Chemother 2015; 59: 6266-6273.
33. Goldstein EJ, Citron DM, Tyrrell KL, et al. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 Gram-positive and Gram-negative aerobic and anaerobic intestinal flora isolates. Antimicrob Agents Chemother 2013; 57: 4872-4876.
34. Corbett D, Wise A, Payne LJ, et al. SMT19969: In vitro pharmacodynamics against Clostridium difficile. Twenty-third European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany; 2013.
35. Sattar A, Thommes P, Payne L, et al. SMT19969 for Clostridium difficile infection (CDI): In vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI. J Antimicrob Chemother 2015; 70: 1757-1762.
36. Weiss W, Pulse M, Vickers R. In vivo assessment of SMT19969 in a hamster model of Clostridium difficile infection. Antimicrob Agents Chemother 2014; 58: 5714-5718.
37. Baines SD, Crowther GS, Freeman J, et al. SMT19969 as a treatment for Clostridium difficile infection: An assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. J Antimicrob Chemother 2015; 70: 182-189.
38. Vickers R, Robinson N, Best E, et al. A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections. BMC Infect Dis 2015; 15: 1.
39. Vickers RJ, Tillotson GS, Nathan R, et al. Ridinilazole for Clostridium difficile infections: Safety and efficacy compared with vancomycin from the CoDIFy phase 2 trial. European Congress Clinical Microbiology and Infectious Disease, Amsterdam, the Netherlands; 2016. Abstract EP0177.
40. Kaleko M, Bristol JA, Hubert S, et al. Development of SYN-004, an oral betalactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection. Anaerobe 2016. [Epub ahead of print]
41. Connelly S, Widmer G, Mukherjee J, et al. SYN-004, a clinical stage oral betalactamase therapy, protects the intestinal microflora from antibiotic-mediated damage in humanized pigs. Gastroenterology 2015; 148: S1195.
42. Roberts T, Kokai-Kun JF, Coughlin O, et al. Tolerability and Pharmacokinetics of SYN-004, an orally administered b-lactamase for the prevention of Clostridium difficile-associated disease and antibiotic-associated diarrhea, in two phase I studies. Clin Drug Invest 2016; 36: 725-734.
43. de Gunzburg J, Ducher A, Modess C, et al. Targeted adsorption of molecules in the colon with the novel adsorbent-based Medicinal Product, DAV132: A proof of concept study in healthy subjects. J Clin Pharmacol 2015; 55: 10-16.
44. Lee BY, Popovich MJ, Tian Y, et al. The potential value of Clostridium difficile vaccine: An economic computer simulation model. Vaccine 2010; 28: 5245-5253.
45. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000; 342: 390-397.
46. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357: 189-193.
47. Kuehne SA, Cartman ST, Heap JT, et al. The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010; 467: 711-713.
48. Pé chiné S, Gleizes A, Janoir C, et al. Immunological properties of surface proteins of Clostridium difficile. J Med Microbiol 2005; 54: 193-196.
49. Foglia G, Shah S, Luxemburger C, et al.Clostridium difficile: Development of a novel candidate vaccine. Vaccine 2012; 30: 4307-4309.
50. Kotloff KL, Wasserman SS, Losonsky GA, et al. Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immunity 2001; 69: 988-995.
51. de Bruyn G, Saleh J, Workman D, et al. Defining the optimal formulation and schedule of a candidate toxoid vaccine against Clostridium difficile infection: A randomized phase 2 clinical trial. Vaccine 2016; 34: 2170-2178.
52. Donald RG, Flint M, Kalyan N, et al. A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile. Microbiology 2013; 159: 1254-1266.
53. Sheldon E, Kitchin N, Peng Y, et al. A phase 1, placebo-controlled, randomized study of the safety, tolerability, and immunogenicity of a Clostridium difficile vaccine administered with or without aluminum hydroxide in healthy adults. Vaccine 2016; 34: 2082-2091.
54. Valneva Se, France. Press release November 2015. http://www.valneva.com/en/investors-media/news. [Accessed 19 September 2016].
55. Permpoonpattana P, Hong HA, Phetcharaburanin J, et al. Immunization with Bacillus spores expressing toxin A peptide repeats protects against infection with Clostridium difficile strains producing toxins A and B. Infect Immunity 2011; 79: 2295-2302.
56. Wilcox, M. et al. Bezlotoxumab alone and with actoxumab for prevention of recurrent C.difficile infection in patients onstandard ofcare antibiotics: Integrated results of 2 Phase 3 studies (MODIFY I andMODIFY II).Open ForumInfect. Dis. [online], http://ofid.oxfordjournals.org/content/2/suppl-1/67.short (2015). Abstract data from phase 3 clinical trials of bezlotoxumab, a monoclonal antibody against C. difficile toxin B, showing approximately 40% relative reduction in recurrent CDI when given with standard of care antibiotics.
57. Golan Y, Dubberke E, Hanson M, et al. Bezlotoxumab (BZO) decreases recurrence and is associated with a reduction in 30-day Clostridium difficile infection-associated readmissions in hospitalized patients with CDI. ASM Microbe 2016; Boston. Abstract 449.
58. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368: 407-415.
59. Lee CH, Steiner T, Petrof EO, et al. Frozen vs fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: A randomized clinical trial. JAMA 2016; 315: 142-149.
60. Youngster I, Russell GH, Pindar C, et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA 2014; 312: 1772-1778.
61. Orenstein R, Dubberke E, Hardi R, et al., PUNCH CD Investigators. Safety and durability of RBX2660 (microbiota suspension) for recurrent Clostridium difficile infection: Results of the PUNCH CD study. Clin Infect Dis 2016; 62: 596-602.
62. Khanna S, Pardi DS, Kelly CR, et al. A novel microbiome therapeutic increases gut microbial diversity and prevents recurrent Clostridium difficile infection. J Infect Dis 2016; 214: 173-181.
63. Gerding DN, Meyer T, Lee C, et al. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: A randomized clinical trial. JAMA 2015; 313: 1719-1727.